Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| IQV | INST-CLUSTER | neutral | 3/10 | A mixed institutional cluster in IQV shows 5 buyers adding $94.4M in new positions (led by Artemis doubling its stake to | Oct 23, 2026 |
| BMY | INST-CLUSTER | neutral | 3/10 | Four asset managers added BMY positions in Q3 2026, with aggregate buying of $18.3M, while one large holder trimmed $25. | Oct 23, 2026 |
| INCY | INST-CLUSTER | bullish | 4/10 | Ten institutional asset managers collectively added $95.2M in new INCY positions during Q3 2026, with zero sellers. The | Oct 23, 2026 |
| ALNY | INST-CLUSTER | bearish | 4/10 | Institutional activity in ALNY during 2026-Q3 shows a mixed picture: 7 small asset managers accumulated $2.6M in net new | Oct 23, 2026 |
| ABEO | SC 13D | bullish | 6/10 | James Russell, through his revocable trust, filed a Schedule 13D disclosing a 6.1% stake in Abeona Therapeutics after co | Oct 23, 2026 |
| RDY | 6-K | bearish | 6/10 | Dr. Reddy's reported Q2 FY2027 (three months ended September 30, 2026) results showing a 2% YoY revenue decline to Rs.86 | Oct 23, 2026 |
| GMAB | 6-K | bullish | 7/10 | Genmab announced positive topline Phase 3 RAINFOL-02 results for Rina-S in platinum-resistant ovarian cancer, meeting bo | Oct 23, 2026 |
| ONCO | DEFA14A | neutral | 2/10 | Onconetix filed a DEFA14A (definitive additional proxy soliciting materials) disclosing an additional $500,000 advance t | Oct 23, 2026 |
| ONCO | 8-K | neutral | 3/10 | Onconetix made an additional $500,000 advance to Realbotix under an existing Grid Promissory Note, bringing total outsta | Oct 23, 2026 |
| CATX | 8-K | bullish | 6/10 | Perspective Therapeutics reported updated interim Phase 1/2a data for [212Pb]VMT-α-NET (bamzireotide navoxetan) in SSTR2 | Oct 23, 2026 |
| BOLT | 8-K | mixed | 7/10 | Bolt Biotherapeutics (BOLT) has entered into a definitive merger agreement to acquire Prana Therapies in a reverse-merge | Oct 23, 2026 |
| ONCO | 425 | bearish | 6/10 | Onconetix advanced an additional $500,000 to Realbotix LLC under the existing Grid Note facility, bringing total draws t | Oct 23, 2026 |
| PRFX | 6-K | neutral | 4/10 | PRF Technologies issued a shareholder letter providing preliminary, unaudited financial highlights for the nine months e | Oct 23, 2026 |
| EIKN | 8-K | neutral | 4/10 | Eikon Therapeutics presented initial and updated clinical data from its PARP1-selective (EIK1003, EIK1004) and WRN helic | Oct 23, 2026 |
| NBP | 6-K | neutral | 3/10 | NovaBridge Biosciences reported that clinical data from the ongoing Phase 1 trial of ragistomig (ABL503/TJ-L14B), a PD-L | Oct 23, 2026 |
| PRFX | PRESS-RELEASE | neutral | 5/10 | PRF Technologies issued a shareholder letter highlighting a strengthened balance sheet with $11M cash and $2.5M liabilit | Oct 23, 2026 |
| GDTC | SC 13G/A | neutral | 3/10 | mDR Ltd filed an amended Schedule 13G disclosing a 9.984% passive stake in CytoMed Therapeutics as of October 12, 2026, | Oct 23, 2026 |
| ORIC | 8-K | bullish | 7/10 | ORIC Pharmaceuticals presented updated Phase 1b data for enozertinib in 1L EGFR atypical NSCLC at ESMO 2026, showing an | Oct 23, 2026 |
| SXTP | 8-K | neutral | 4/10 | 60 Degrees Pharmaceuticals filed an 8-K furnishing an updated investor presentation (October 23, 2026) detailing progres | Oct 23, 2026 |
| NEUP | 8-K | neutral | 2/10 | Neuphoria Therapeutics extended the expiration date of its shareholder rights plan (poison pill) by one year, from Octob | Oct 23, 2026 |
| IMTX | 6-K | bullish | 7/10 | Immatics N.V. released updated Phase 1 data for its IMA203CD8 PRAME-directed TCR T-cell therapy, showing a 51% objective | Oct 23, 2026 |
| BLRX | 6-K | bullish | 5/10 | BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple PARP inhibitor | Oct 23, 2026 |
| SPRC | 6-K | neutral | 4/10 | SciSparc subsidiary NeuroThera Labs announced operational progress in its FDA-approved Phase IIb trial of SCI-110 for To | Oct 23, 2026 |
| TNGX | 8-K | bullish | 7/10 | Tango Therapeutics reported highly promising Phase 1/2 data for vopimetostat + daraxonrasib in MTAP-deleted PDAC, showin | Oct 23, 2026 |
| IMMP | 20-F | bearish | 7/10 | Immutep's FY2026 20-F annual report confirms the devastating impact of the TACTI-004 Phase III trial discontinuation in | Oct 23, 2026 |
| QGEN | 6-K | bullish | 8/10 | QIAGEN N.V. announced a definitive agreement to be acquired by Crown NL Bidco B.V., an EQT-backed entity, via a public t | Oct 23, 2026 |
| ZYME | 8-K | bullish | 7/10 | Zymeworks entered into an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T-cel | Oct 23, 2026 |
| ZLAB | 8-K | bullish | 6/10 | Zai Lab announced a $250M PIPE financing, selling 11.34M ADSs at $22.04/ADS to a syndicate of healthcare-focused investo | Oct 23, 2026 |
| ATHE | 6-K | bearish | 6/10 | Alterity Therapeutics filed a 6-K with an Exhibit 99.1 titled 'Proposed issue of securities - ATH', indicating a planned | Oct 23, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K with an exhibit (Exhibit 99.1) titled 'Notification regarding unquoted securities | Oct 23, 2026 |